01 · MSC vs Exosome
The decision matrix
When MSCs outperform, when exosomes are equivalent or better, and the indications where the regulatory delta makes the choice for you.
🇲🇽 Cancún · Day 3 · Sunday, Sept 27, 2026 · Physicians Only · Limited
Advanced MSCs & Exosome Certification.
Mesenchymal stem cells and exosome therapeutics — sourcing standards, dose-by-indication matrices, and the cell-free regenerative protocols changing what's possible in clinic. The most intimate ISSCA cohort of the summit: 25 physicians, 3 of the field's leading clinician-scientists.
Day 3 · Sunday Sept 27, 2026
From cell-based to cell-free regeneration.
A full clinical day at Cellgenic Lab — 2 parallel groups led by Dr. Keith March (the clinician who coined "secretome") and Andrea Lapeire. MSC foundations, exosome biology, dosing trees and a supervised hands-on demo with patient.
Day 3 · Cellgenic Lab
2 parallel groups
Physicians only
Included
Faculty-Led Curriculum
Dr. Keith March and Andrea Lapeire — MSC foundations, allogeneic vs autologous, exosome & secretome biology.
Included
Clinical Applications
Indications by system — MSK, neuro, cardio, autoimmune, dermatology — with dosing trees and biomarker selection.
Included
Hands-On with Patient
Supervised clinical demonstration · live MSC + exosome handling at the lab.
Included
Safety & Compliance
GMP, traceability, adverse-event monitoring · the regulatory framework that protects your clinic.
Included
ISSCA Certification
Official ISSCA Advanced MSCs & Exosome Certification — internationally recognized in 30+ countries.
Included
Hotel→Lab Transfer
Dedicated MSCs bus from the host hotel to Cellgenic Lab and back — fully included.
— 02 / What you'll master
Six skills you walk out with.
By 6 PM Sunday you can confidently choose between MSCs and exosomes, source from a vetted partner, dose by indication, and monitor outcomes that contribute to the field's evidence base.
02 · Sourcing
Donor-screening checklist
Tissue source (umbilical cord vs adipose vs bone marrow), donor screening, characterization standards, batch testing and cold-chain logistics.
03 · Indication Mapping
Dose-by-indication matrix
A printable matrix: indication → MSC vs exosome → cell count or particle count → route → schedule. The matrix our faculty actually uses.
04 · Routes & Schedules
IV · IA · IT · topical
Route by indication, infusion-rate protocols, premedication, booster timing, and the scenarios where route changes outcome.
05 · Safety & Documentation
AE protocol + paperwork
Watch-list at hour 1, day 1, week 1, month 1. Escalation pathway. Consent forms, intake forms, the documentation trail that protects your clinic.
06 · Outcome Tracking
Registry & reporting
How to enter outcomes into the ISSCA registry, the minimum dataset, and how that contributes to the field-wide evidence the clinic needs.
— Key Clinical Topics
Five clinical topics, decoded.
Each topic comes with the dose-by-indication matrices, sourcing guides and adverse-event playbooks we use in daily practice.
Mechanism of action, what MSCs actually secrete, and why exosomes carry most of the regenerative payload — the case for cell-free where it applies.
- Paracrine vs differentiation
- Secretome composition
- Exosome cargo
- microRNA payload
- Growth-factor profile
- Cell-free vs cell-based decision
Tissue source comparison (cord, adipose, bone marrow). ISCT criteria. Particle-count standards. Cold-chain. Vetted sourcing partners.
- Cord vs adipose vs marrow
- ISCT characterization criteria
- Particle-count standards
- Cold-chain logistics
- Vetted sourcing partners
- Regulatory framework
The dose-by-indication matrix. MSC vs exosome decision tree. The four indications where exosomes already outperform MSCs in our faculty's practice.
- Dose-by-indication matrix
- MSC vs exosome decision tree
- Top 4 exosome-first indications
- Combination protocols
- Outcome timelines
- Re-treatment cadence
IV vs intra-articular vs intrathecal vs topical. Cell count and particle count by route. Infusion-rate protocols. Booster timing.
- IV protocol
- Intra-articular protocol
- Intrathecal protocol
- Topical / micro-needled protocols
- Cell-count vs particle-count
- Booster-timing tables
Hour-1, day-1, week-1, month-1 watch lists. AE escalation pathway. Documentation trail. ISSCA registry entry that contributes to field-wide evidence.
- Hour-1 / day-1 / week-1 / month-1 watch lists
- AE escalation pathway
- Consent-form template
- Documentation trail
- ISSCA registry workflow
- Outcome-tracking dataset
— 03 / Day 3 Curriculum
Lab visit, four clinical cases, two hours of Q&A.
Sunday, September 27, 2026 — laboratory walk-through of MSC and exosome handling, four applied clinical cases (Hashimoto, lumbar radiculopathy, ischemic stroke), then a full two-hour open Q&A. Two simultaneous groups · same agenda · faculty-signed certificate at close.
01
10:00 – 10:10 — Welcome & General Introduction
Opening of the program — academic objectives and clinical framing for advanced exosome and MSC applications.
02
10:10 – 10:45 — Laboratory Visit
Walk-through of the stem-cell and exosome thawing and preparation process at Cellgenic Laboratory Facilities.
03
11:00 – 11:30 — Case 1 · Hashimoto's Thyroiditis with Exosomes + Peptide Stack
Applied clinical case — protocol design, patient evaluation, exosome + peptide combination strategy and follow-up criteria.
04
11:30 – 11:40 — Coffee Break
Networking break.
05
11:40 – 12:10 — Case 2 · Lumbar Pain & Radiculopathy with Exosomes + Peptide Stack
Applied clinical case — selection, dosing, route choice and combined protocol for chronic lumbar radiculopathy.
06
12:10 – 12:40 — Case 3 · Lumbar Radiculopathy — IV Variation
Variation on the lumbar protocol using IV exosomes + peptides — when to choose IV over localized routes, monitoring and response criteria.
07
13:00 – 14:00 — Case 4 · Ischemic Stroke with Neurological Sequelae · Nebulized Exosomes + MOTS-C SC
Complex clinical case — nebulized exosome delivery combined with subcutaneous MOTS-C. Protocol design, timing, neurological follow-up and integration with rehabilitation.
08
14:00 – 15:00 — Lunch
Plated lunch.
09
15:00 – 17:00 — Open Q&A · Case Discussion
Two-hour interactive forum. Open discussion, reflection on the day's cases, your own patient questions and protocol clarifications with faculty.
10
17:00 – 17:30 — Academic Closing · Toast & Certificate Ceremony
Closing toast and ISSCA International Certification ceremony. Both groups close simultaneously at Cellgenic Lab.
— 04 / Faculty
Three clinician-scientists, Limited.
A 1:8 faculty-to-attendee ratio — the most intimate cohort on the summit. Every attendee leaves with two of their own cases reviewed by faculty.
Dr. Keith L. March, MD, PhD
Lead Faculty · Cell-Free Regenerative Therapies
Pioneer of cell-free regenerative therapeutics — coined the term "secretome." Decades of translational research on what MSCs secrete and how to deliver the payload without the cell.
Dr. Andrea Lapeire
Faculty · Group 1 · Clinical Implementation
Argentina's leading regenerative-medicine clinician with deep MSC and exosome practice. Leads Group 1 hands-on at Cellgenic Lab.
— 05 / Recognition
Earn your official ISSCA certification.
Faculty-signed, registered in the ISSCA member portal, recognized by 12,000+ ISSCA-certified physicians across 30+ countries.
Official Certification
ISSCA Accredited
Global Recognition
30+ Countries
Faculty-Signed
March · Lapeire
Day 3 · Track
Sunday Sept 27 · Included
Hands-On Practice
1 Day · Clinical
Limited
First Verified, First Confirmed
ISSCA
International Society for Stem Cell Application
This certifies that
Dr. María García-López, MD
has successfully completed the advanced certification program in
MSCs & Exosomes
Join 12,000+ certified physicians worldwide
ISSCA-accredited · 30+ countries · Faculty-signed by March · Lapeire
— Testimonials
What Physicians Say About ISSCA Events
Since 2010, ISSCA has trained 12,000+ physicians across 30+ countries. Hear directly from peers who already apply these protocols in their clinics.
— 06 / Pricing
Two pricing windows. Limited. Physicians only.
Early Bird closes May 31, 2026. After that, hold your seat with a $1,000 deposit — $2,500 balance due before the event.
Early Bird closes May 31, 2026
—Days
—Hours
—Min
—Sec
MSCs & Exosomes — Early Bird
Closes May 31, 2026
$2,500 $3,500
- Full Day-2 protocol certification (Sept 27)
- Sourcing, indication mapping & safety modules
- Take-home dose-by-indication matrices + sourcing guide
- Faculty-signed ISSCA certificate
- Access to the ISSCA MSC / exosome outcome registry
- Lifetime access to ISSCA cell-therapy protocol updates
MSCs & Exosomes — Reservation
After May 31 · balance due before Sept 27, 2026
$1,000
- Full Day-2 protocol certification (Sept 27)
- Sourcing, indication mapping & safety modules
- Take-home dose-by-indication matrices + sourcing guide
- Faculty-signed ISSCA certificate
- Access to the ISSCA MSC / exosome outcome registry
- Lifetime access to ISSCA cell-therapy protocol updates
Sunday certification participants receive Saturday's full conference recordings. Bundle with the full Global Summit pass at checkout to attend Saturday in person.
— 09 / Venue & Logistics
Cancún Hotel Zone
Oceanfront resort · Caribbean, Quintana Roo, México
~20–30 min
28–32°C
Need a Visa Letter?
Contact info@stemcellsgroup.com with your passport details after registration. Direct flights from USA, Canada, Mexico, Colombia, Argentina, Spain, Italy, Portugal and UAE.
— 08 / FAQ
Common questions.
MSC and exosome therapy are physician-prescribed cellular therapies. Patient workup, dosing decisions and adverse-event escalation belong squarely with a licensed MD or DO. The Limited cap protects the 1:8 faculty-to-attendee ratio that makes the case-review block actually work for every attendee.
Sourcing varies by jurisdiction. The certification covers the regulatory landscape and lists the vetted sourcing partners ISSCA faculty work with. We'll cover your country's framework explicitly during sourcing & standards.
This is a protocol-and-decision-making certification, not a live-infusion workshop. The day is structured around patient case-work, dosing matrices and safety drills — the highest-leverage skills for clinic implementation.
MUSE-cell therapy is a specific cell type with its own clinical playbook (homing, low-tumorigenicity, indication set). The MSC + Exosome track is the broader cell-therapy and cell-free framework — most clinics start here and then add MUSE as a third option for the indications where MUSE outperforms.
Full refund until May 31. 50% refund June 1 – Aug 1. Non-refundable after Aug 1. Free transfer to another physician at your clinic up to 14 days pre-event. Force-majeure: credit carried to the next ISSCA event.
Sunday certification participants get the Saturday conference recordings on the ISSCA member portal. To attend Saturday in person, bundle the full ISSCA Global Summit pass at checkout.
Combine & Save
Upgrade your experience — get 15% off both certifications.
Pair this certification with one of the parallel tracks running on the complementary day. The 15% bundle discount applies to your full enrollment.
— Day 3 · Sunday, Sept 27
Limited. Physicians only. Early Bird closes May 31.
The most intimate cohort of the summit — three of the field's leading clinician-scientists, your patient cases, the protocols.